Bioxcel Therapeutics Stock Analysis
| BTAI Stock | USD 1.72 0.08 4.44% |
BioXcel Therapeutics is undervalued with Real Value of 2.27 and Target Price of 2.81. The main objective of BioXcel Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what BioXcel Therapeutics is worth, separate from its market price. There are two main types of BioXcel Therapeutics' stock analysis: fundamental analysis and technical analysis.
The BioXcel Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BioXcel Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
BioXcel |
BioXcel Stock Analysis Notes
About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 33.01. BioXcel Therapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 10th of February 2025. BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. Bioxcel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on BioXcel Therapeutics please contact Vimal Mehta at 475 238 6837 or go to https://www.bioxceltherapeutics.com.BioXcel Therapeutics Investment Alerts
| BioXcel Therapeutics generated a negative expected return over the last 90 days | |
| BioXcel Therapeutics has high historical volatility and very poor performance | |
| BioXcel Therapeutics may become a speculative penny stock | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| BioXcel Therapeuticshas 4,011,254 shares shorted by BioXcel Therapeutics investors is about 100% of outstending shares | |
| The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 251 K. | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioXcel Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioXcel Therapeutics announces 1-for-16 reverse stock split - MSN |
BioXcel Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioXcel Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
BioXcel Largest EPS Surprises
Earnings surprises can significantly impact BioXcel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-08-06 | 2019-06-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2019-03-07 | 2018-12-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2019-11-14 | 2019-09-30 | -0.65 | -0.57 | 0.08 | 12 |
BioXcel Stock Institutional Investors
| Shares | Arete Wealth Advisors, Llc | 2024-09-30 | 40.5 K | Diversify Wealth Management, Llc | 40 K | Hennion & Walsh Asset Management Inc | 2024-12-31 | 39.4 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 38 K | Susquehanna International Group, Llp | 2024-09-30 | 34.2 K | Group One Trading, Lp | 2024-09-30 | 30.2 K | Squarepoint Ops Llc | 2024-09-30 | 23.7 K | Lpl Financial Corp | 2024-09-30 | 17.5 K | Point72 Asia (singapore) Pte. Ltd | 2024-09-30 | 15.2 K | Blackrock Inc | 2024-12-31 | 380.6 K | Geode Capital Management, Llc | 2024-09-30 | 298 K |
BioXcel Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.58 M.BioXcel Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.19) | (2.30) | |
| Return On Capital Employed | (4.25) | (4.04) | |
| Return On Assets | (2.19) | (2.30) | |
| Return On Equity | 3.64 | 3.83 |
Management Efficiency
BioXcel Therapeutics has return on total asset (ROA) of (0.6212) % which means that it has lost $0.6212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Return On Equity is estimated to increase to 3.83, while Return On Tangible Assets are projected to decrease to (2.30). As of now, BioXcel Therapeutics' Non Current Assets Total are increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.30, while Non Currrent Assets Other are projected to decrease to under 95 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.75) | (1.66) | |
| Tangible Book Value Per Share | (1.75) | (1.66) | |
| Enterprise Value Over EBITDA | (7.68) | (8.06) | |
| Price Book Value Ratio | (21.90) | (22.99) | |
| Enterprise Value Multiple | (7.68) | (8.06) | |
| Price Fair Value | (21.90) | (22.99) | |
| Enterprise Value | 7.5 B | 5.6 B |
Evaluating the management effectiveness of BioXcel Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioXcel Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 27th of February, BioXcel Therapeutics shows the Mean Deviation of 6.45, risk adjusted performance of (0.15), and Standard Deviation of 9.64. BioXcel Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioXcel Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BioXcel Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BioXcel Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BioXcel Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioXcel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioXcel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioXcel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioXcel Therapeutics Outstanding Bonds
BioXcel Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioXcel Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioXcel bonds can be classified according to their maturity, which is the date when BioXcel Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
BioXcel Therapeutics Predictive Daily Indicators
BioXcel Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioXcel Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 1.72 | |||
| Day Typical Price | 1.72 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.08) | |||
| Relative Strength Index | 31.83 |
BioXcel Therapeutics Forecast Models
BioXcel Therapeutics' time-series forecasting models are one of many BioXcel Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioXcel Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About BioXcel Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioXcel Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioXcel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioXcel Therapeutics. By using and applying BioXcel Stock analysis, traders can create a robust methodology for identifying BioXcel entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (116.77) | (122.61) | |
| Operating Profit Margin | (112.03) | (117.63) | |
| Net Loss | (116.77) | (122.61) | |
| Gross Profit Margin | 0.10 | 0.10 |
Current BioXcel Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioXcel analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioXcel analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 2.81 | Buy | 4 | Odds |
Most BioXcel analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioXcel stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioXcel Therapeutics, talking to its executives and customers, or listening to BioXcel conference calls.
BioXcel Stock Analysis Indicators
BioXcel Therapeutics stock analysis indicators help investors evaluate how BioXcel Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioXcel Therapeutics shares will generate the highest return on investment. By understating and applying BioXcel Therapeutics stock analysis, traders can identify BioXcel Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 193.7 M | |
| Long Term Debt | 100.6 M | |
| Common Stock Shares Outstanding | 29.1 M | |
| Total Stockholder Equity | -56.5 M | |
| Property Plant And Equipment Net | 1.5 M | |
| Cash And Short Term Investments | 65.2 M | |
| Cash | 65.2 M | |
| Accounts Payable | 13.7 M | |
| Net Debt | 36.2 M | |
| 50 Day M A | 5.0072 | |
| Total Current Liabilities | 27.3 M | |
| Other Operating Expenses | 173.2 M | |
| Non Current Assets Total | 1.6 M | |
| Non Currrent Assets Other | 87 K | |
| Stock Based Compensation | 18.6 M |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |